Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
RIO
-0.3300
The Fort Worth Press - Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
USD
-
AED 3.672501
AFN 65.000146
ALL 81.796087
AMD 360.510267
ANG 1.789785
AOA 918.000074
ARS 1544.623977
AUD 1.468246
AWG 1.8
AZN 1.703419
BAM 1.763754
BBD 2.014781
BDT 124.426207
BGN 1.747831
BHD 0.377416
BIF 3024.561372
BMD 1
BND 1.28556
BOB 11.709376
BRL 5.615702
BSD 1.000311
BTN 94.028525
BWP 13.87828
BYN 3.01383
BYR 19600
BZD 2.011895
CAD 1.42619
CDF 2315.000159
CHF 0.833902
CLF 0.025158
CLP 990.36943
CNY 6.67035
CNH 6.67075
COP 3307.41
CRC 451.637049
CUC 1
CUP 24.008658
CVE 99.439517
CZK 22.02455
DJF 178.137907
DKK 6.75187
DOP 60.693238
DZD 136.856982
EGP 53.437135
ERN 15
ETB 163.33885
EUR 0.90318
FJD 2.269699
FKP 0.753031
GBP 0.755015
GEL 2.615223
GGP 0.753031
GHS 11.713885
GIP 0.753031
GMD 73.999599
GNF 8862.956934
GTQ 7.643921
GYD 209.287015
HKD 7.844725
HNL 26.899577
HRK 6.76901
HTG 131.072142
HUF 329.957979
IDR 18249
ILS 3.200198
IMP 0.753031
INR 94.03105
IQD 1516.519292
IRR 1906074.999701
ISK 123.295602
JEP 0.753031
JMD 158.465486
JOD 0.709038
JPY 159.850498
KES 129.940245
KGS 87.448901
KHR 4122.27027
KMF 442.000354
KPW 899.999961
KRW 1334.73501
KWD 0.30968
KYD 0.833653
KZT 444.305162
LAK 22511.50962
LBP 89581.865979
LKR 332.667481
LRD 170.058303
LSL 16.673626
LTL 2.95274
LVL 0.60489
LYD 6.450624
MAD 9.853409
MDL 18.24675
MGA 4565.971205
MKD 55.56709
MMK 2099.724407
MNT 3604.903758
MOP 8.08194
MRU 40.45723
MUR 47.360045
MVR 15.416915
MWK 1734.672252
MXN 18.62908
MYR 4.079202
MZN 63.899565
NAD 16.673626
NGN 1346.570013
NIO 36.812748
NOK 9.566995
NPR 150.445279
NZD 1.801955
OMR 0.384482
PAB 1.000401
PEN 3.410816
PGK 4.563225
PHP 63.795955
PKR 276.623544
PLN 3.978735
PYG 6201.019074
QAR 3.646661
RON 4.829396
RSD 106.218992
RUB 82.94774
RWF 1477.740552
SAR 3.774844
SBD 8.090747
SCR 13.853673
SDG 601.502932
SEK 9.998565
SGD 1.286545
SHP 0.749316
SLE 22.903834
SLL 20969.504398
SOS 571.670778
SRD 37.503968
STD 20697.981008
STN 22.094864
SVC 8.752937
SYP 13001.999685
SZL 16.662233
THB 33.861026
TJS 9.228216
TMT 3.5
TND 3.011043
TOP 2.40776
TRY 50.257865
TTD 6.795298
TWD 32.994306
TZS 2659.573959
UAH 45.456661
UGX 4116.859283
UYU 40.546512
UZS 11974.568246
VES 900.490501
VND 25679.5
VUV 119.943861
WST 2.787799
XAF 592.446922
XAG 0.020065
XAU 0.000258795488
XCD 2.70255
XCG 1.802851
XDR 0.707052
XOF 592.446922
XPF 107.551415
YER 236.499474
ZAR 16.743705
ZMK 9001.204186
ZMW 20.431887
ZWL 321.999592
SSP 5786.523514
MXV 2.092613
- Over-75s Face 25% Surge in Emergency Department Delays
- Barbie sequel negotiations stall over reported $25 million pay packages
- João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
- Bath & Body Works launches buy-one-get-one-free candle offer
- Itlu Arjuna receives U/A certificate ahead of theatrical release
- Dhananjaya de Silva guides Sri Lanka to 221-4 against Pakistan
- Niraj Kumar earns Los Angeles Olympic quota with 50m rifle bronze
- Delhi gold loses Rs 800 while silver falls Rs 5,000
- India extends micro-credit guarantee plan for five years
- Pradeep Antony, Smeha Manimegalai portray secret spouses in Mr & Mrs Office
Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
- Video webcast now available on-demand
AURORA, CO / ACCESS Newswire / July 22, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced Soren Mogelsvang PhD, President and Chief Executive Officer and Founder of Exxel, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
As part of the event, Dr. Mogelsvang dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Company's website (exxelpharma.com).
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company's lead program, EX937, is a novel, oral, patented small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel plans to launch a first-in-human Phase 1/1b study of EX937 for the treatment of refractory chronic cough, a large underserved market with no current FDA-approved therapies. In preclinical studies, EX937 demonstrated efficacy in its ability to modulate chronic cough in multiple models. Additionally, EX937 has shown to have a favorable preclinical safety profile and is expected to have no CNS side effects by being entirely excluded from the central nervous system and brain. EX937 also has the potential to be utilized across a number of high-value indications, including hyperactive bladder, peripheral neuropathic pain and migraine headaches. Exxel Pharma has a second program (ARN compounds) with the potential to treat Social Anxiety and Autism Spectrum Disorder.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
E: [email protected]
SOURCE: Exxel Pharma, Inc.
View the original press release on ACCESS Newswire
T.Mason--TFWP
